Please check your internet connection and try again.
# Arsil dx
## Overview
Arsil dx is a fixed-dose combination product. The exact composition needs to be confirmed as the provided name is unclear due to excessive encoding. If "Arsil dx" refers to a combination of **Artemether and Lumefantrine**, it is an antimalarial agent. If it refers to another combination, specific details are required.
## Primary Indications
If Artemether/Lumefantrine:
* Treatment of uncomplicated *Plasmodium falciparum* malaria in patients weighing at least 5 kg.
## Adult Dosing
If Artemether/Lumefantrine:
* **Standard Dosing:** 4 tablets (20mg Artemether/120mg Lumefantrine per tablet) at 0, 8, 24, and 48 hours (total of 4 doses).
* **Maximum Dose:** Not explicitly defined beyond the standard regimen, but individual doses are fixed by tablet strength.
## Pediatric Dosing
If Artemether/Lumefantrine:
* **Weight-based Dosing:**
* 5 to <15 kg: 1 tablet at 0, 8, 24, and 48 hours.
* 15 to <25 kg: 2 tablets at 0, 8, 24, and 48 hours.
* 25 to <35 kg: 3 tablets at 0, 8, 24, and 48 hours.
* ≥35 kg: 4 tablets at 0, 8, 24, and 48 hours.
## Dose Adjustments
* **Hepatic Impairment:** Caution is advised. Data is limited, but dose reduction may be considered based on clinical judgment and monitoring.
* **Renal Impairment:** No specific dose adjustments are typically recommended, but monitor for adverse effects.
## Contraindications
If Artemether/Lumefantrine:
* Known hypersensitivity to artemether, lumefantrine, or any component of the formulation.
* Severe malaria.
* Cardiac arrhythmias.
* Concomitant use with certain QT-prolonging drugs.
## Adverse Effects
Common adverse effects may include:
* Nausea, vomiting, diarrhea, abdominal pain
* Headache, dizziness
* Fatigue, malaise
* Anorexia
* Anemia, neutropenia, thrombocytopenia
* Transient elevations in liver enzymes
* Palpitations, QT interval prolongation (rare but serious)
## Key Drug Interactions
If Artemether/Lumefantrine:
* **CYP3A4 Inhibitors/Inducers:** May alter plasma concentrations of artemether and lumefantrine.
* **QT-Prolonging Agents:** Increased risk of QTc interval prolongation and arrhythmias. Examples include certain antiarrhythmics, antipsychotics, and macrolide antibiotics.
* **Antimalarials:** Avoid concurrent use of other antimalarials that have shown cross-resistance or potential antagonism.
* **Grapefruit Juice:** May increase lumefantrine concentrations.
## Monitoring
* **Malaria Parasitemia:** Monitor for resolution of parasitemia.
* **Liver Function Tests:** Baseline and periodic monitoring, especially in patients with hepatic impairment or those on prolonged therapy.
* **Electrocardiograms (ECGs):** Consider baseline and follow-up ECGs, particularly in patients with risk factors for QT prolongation or those taking other QT-prolonging drugs.
* **Complete Blood Count (CBC):** Monitor for anemia, neutropenia, and thrombocytopenia.
* **Clinical Symptoms:** Assess for improvement in malaria symptoms.
## Clinical Pearls
* Artemether/Lumefantrine should be taken with food or a fatty meal to maximize absorption of lumefantrine.
* Consider co-administration of a fatty food equivalent for infants and young children.
* Treatment failure can occur, necessitating careful follow-up to ensure parasite clearance.
* The possibility of counterfeit antimalarials should be considered, especially in endemic areas.
***
**Disclaimer:** This information is intended for clinical professionals and is not a substitute for the manufacturer's current prescribing information or institutional guidelines. Always verify the exact drug composition and consult the most up-to-date product monograph for complete and current details before prescribing.
